🕒 Last update: loading…21/11/2026

Stock Cardiff Oncology, Inc. CRDF

Cardiff Oncology, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -61.01%

Price change 2019 → 2020: 1350.81%

Price change 2020 → 2021: -66.59%

Price change 2021 → 2022: -76.71%

Price change 2022 → 2023: 5.71%

Price change 2023 → 2024: 193.24%

Price change 2024 → 2025: -35.25%

Price change 2025 → 2026: -69.22%

Price change 2026 (year to date): -67.48%

Financial growth

Revenue CAGR (8 years): 6.64%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.02

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.43

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 55.41% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Cardiff Oncology, Inc.–0.02+5.5 %🔒
DocCheck AG11.30.10+8.9 %–
Fermentalg–0.20+38.5 %–
Klea Holding18.10.20+5.2 %–
FamiCord AG–3.30+11.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Cardiff Oncology, Inc. over the latest fiscal years.

Revenue
593,000 USD
fiscal year 2025
Net income
-45.9 m USD
fiscal year 2025
Net margin
-7,732.0 %
fiscal year 2025
Average annual growth
+10.1 %
Revenue growth over 5 years
Average annual growth
+6.6 %
Revenue growth over 10 years
Market cap
56.5 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020366,000-19.3 m-5,275.1 %n/a
2021359,000-28.3 m-7,880.5 %-1.9 %
2022386,000-38.7 m-10,026.9 %+7.5 %
2023488,000-41.4 m-8,492.0 %+26.4 %
2024683,000-45.4 m-6,651.7 %+40.0 %
2025593,000-45.9 m-7,732.0 %-13.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Cardiff Oncology, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-15.51
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.32 x
low debt
Fiscal year20212022202320242025
Cash and investments141 m105 m74.8 m91.7 m58.3 m
Total Debt3.1 m2.7 m2.1 m1.5 m832,000
Net Debt-8.8 m-13.6 m-19.5 m-49.9 m-16.6 m
Equity140 m106 m69.7 m82.9 m45.4 m
Total assets150 m116 m81.6 m97.2 m61.9 m
Operating cash flow-23.0 m-33.8 m-30.9 m-37.7 m-37.9 m
Investments (capex)205,000892,000582,00080,00044,000
Free cash-flow-23.2 m-34.7 m-31.5 m-37.8 m-38.0 m
Share buybacks00000
Dividends paid24,000414,000000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-1.62 x
Price / book value2.42 x
Return on Equity (ROE)-111.8 %
Return on Invested Capital (ROIC)-139.3 %
Net margin-6,735.2 %
Debt / equity0.01 x
Current ratio4.21 x
Free cash-flow yield-57.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Cardiff Oncology, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Cardiff Oncology, Inc.56.5 mn/a-7,732.0 %
Corbus Pharmaceuticals Holdings, Inc. CRBP69.9 mn/a0.0 %
Elicio Therapeutics, Inc. ELTX28.6 mn/a0.0 %
PepGen Inc. PEPG302 mn/a0.0 %
Rani Therapeutics Holdings, Inc. RANI34.4 mn/a-1,817.1 %
Milestone Pharmaceuticals Inc. MIST64.7 mn/a-4,078.8 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Cardiff Oncology, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
15 analysts

Breakdown of ratings

strong buy 0buy 8hold 6sell 1strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Cardiff Oncology, Inc.

Free float
93.8 %
share of freely traded shares
Large funds tracked
16
hold the stock as of 2026Q2
Executives (insiders)
4 / 0
4 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group3.7 m10.5 m0.0 %+3.7 %2025Q4
BlackRock972,8731.3 m0.0 %-75.6 %2026Q2
Geode Capital Management820,0621.1 m0.0 %-48.7 %2026Q2
State Street662,790861,6280.0 %-44.2 %2026Q2
AQR Capital Management346,353450,2600.0 %+423.5 %2026Q2
Morgan Stanley246,095319,9240.0 %+337.1 %2026Q2
Marshall Wace162,214210,8790.0 %n/a2026Q2
Northern Trust152,875198,7380.0 %-69.0 %2026Q2

Latest insider transactions

DatePersonSideAmount
14/07/2026Pace Gary Wpurchase1,000,000 USD
14/07/2026Pace Gary Wpurchase914,089 USD
14/07/2026Mohindru Manipurchase50,000 USD
14/07/2026Mohindru Manipurchase45,704 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 27/07/2004
ISIN code
US14147L1089
Workforce
32
full-time employees
Chief executive
Mark Erlander

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Cardiff Oncology, Inc.

What is the Cardiff Oncology, Inc. share price?

Latest recorded price: 0.726 USD on 13/11/2026, for a market cap of 56.5 m USD.

What is the revenue of Cardiff Oncology, Inc.?

593,000 USD for fiscal year 2025, with net income of -45.9 m USD (net margin -7,732.0 %).

What do analysts say about Cardiff Oncology, Inc.?

Out of 15 analysts: 8 buy or strong buy, 6 hold, 1 sell or strong sell.

Is Cardiff Oncology, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US14147L1089).

How many employees does Cardiff Oncology, Inc. have?

32 full-time employees according to the latest published profile.

Who runs Cardiff Oncology, Inc.?

Mark Erlander is the company's chief executive.

Which large funds own Cardiff Oncology, Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, BlackRock, Geode Capital Management, State Street, AQR Capital Management.

07

Similar stocks